

Rituximab-PVVR followed by Abatacept Versus Rituximab-PVVR Alone In New Onset Type 1 Diabetes

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: Not specified

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- 8 to 45 years old - diagnosis of Type 1 Diabetes within 100 days of starting the study - positive for at least one islet cell autoantibody - willing to comply with intensive diabetes management - willing to wear a continuous glucose monitoring device for a minimum of 10 days every 6 months - weigh at least 20kg (44 pounds) - up to date on all recommended vaccinations based on age - willing to practice public health prevention measures such as social distancing, masking, and good hand hygiene, and/or receive therapeutics such as monoclonal antibodies and antivirals as directed by the study and recommended by local health authorities to prevent SARS-Cov-2 infection - see link to clinicaltrials.gov for complete inclusion and exclusion criteria

Exclusion Criteria:

- history of immune deficiency - chronic active infection other than localized skin infections - current or past HIV or Hepatitis B or active Hepatitis C infection - women who are pregnant, breast feeding, or anticipate pregnancy - use of oral or inhaled steroids or other immunosuppressive agents - history of cancer

Conditions & Interventions

Conditions:

Diabetes & Endocrine

Keywords:

DM, T1D, Type 1 Diabetes

More Information

Description: This study is to see if giving the medications rituximab-pvvr (Ruxience®) followed by abatacept can help preserve remaining insulin secretion if given within three months of being diagnosed with type 1 diabetes (T1D).

Study Contact: Veronica Jones-Carr - jone2678@umn.edu

Principal Investigator: Antoinette Moran

IRB

Number: STUDY00021237

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.